Mori H, Mori S, Saitoh Y, Arita N, Aono T, Uozumi T, Mogami H, Matsumoto K
Cancer. 1985 Jul 15;56(2):230-8. doi: 10.1002/1097-0142(19850715)56:2<230::aid-cncr2820560204>3.0.co;2-8.
Prolactin-secreting pituitary adenomas were studied to clarify the mechanism by which bromocriptine reduces tumor size. Patients examined consisted of three groups: Group I (four cases) received no medication, Group II (six cases) continued bromocriptine treatment (10 mg/day for 2 weeks) until the operation, and Group III (five cases) discontinued the treatment 1 week before the operation. Adenomas in Group II showed a variety of degenerative and necrotic changes of tumor cells in addition to marked decrease in volume of individual cell. Adenomas in Group III showed divergent structural changes. Irreversible changes seen in Group II became more pronounced with a marked increase in stromal tissue. Proliferative areas consisting of intermediate-sized cells were found in the scarce stromal tissue. The findings seem to indicate that the reduction in size of prolactinomas by bromocriptine treatment results from the reduction in size of individual tumor cell as well as from cell loss secondary to necrosis.
对分泌催乳素的垂体腺瘤进行了研究，以阐明溴隐亭缩小肿瘤大小的机制。所检查的患者分为三组：第一组（4例）未接受药物治疗；第二组（6例）在手术前持续使用溴隐亭治疗（10毫克/天，共2周）；第三组（5例）在手术前1周停止治疗。第二组的腺瘤除单个细胞体积明显减小外，还显示出肿瘤细胞的各种退行性和坏死性变化。第三组的腺瘤显示出不同的结构变化。第二组中所见的不可逆变化随着间质组织的显著增加而更加明显。在稀少的间质组织中发现了由中等大小细胞组成的增殖区域。这些发现似乎表明，溴隐亭治疗使催乳素瘤体积缩小是由于单个肿瘤细胞体积减小以及坏死继发的细胞丢失所致。
